Focus: Xenon Pharmaceuticals is a public biotech focused on small-molecule therapeutics for rare genetic diseases, particularly in neurology and epilepsy, headquartered in Burnaby, BC. The company operates with a lean structure and is advancing multiple late-stage programs toward potential commercialization.
Profile data last refreshed 3h ago · AI intelligence enriched 2mo ago
Growing — net +6 jobs in 30d
16 jobs added vs 10 removed. Steady team buildout.
Best suited for clinical development and commercial professionals seeking high-risk, high-reward exposure to late-stage epilepsy and neuropsychiatric programs with near-term approval potential.
Help build intelligence for Xenon Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Xenon Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Wellington group discloses 1.47% Xenon Pharmaceuticals (XENE) stake for advisory clients - Stock Titan
Wellington group discloses 1.47% Xenon Pharmaceuticals (XENE) stake for advisory clients Stock Titan
FMR LLC (XENE) discloses 9.96M-share, 10.3% holding in Xenon Pharmaceuticals - Stock Titan
FMR LLC (XENE) discloses 9.96M-share, 10.3% holding in Xenon Pharmaceuticals Stock Titan
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Xenon Pharmaceuticals advances with strong Phas... - Pluang
Xenon Pharmaceuticals advances with strong Phas... Pluang
Xenon Pharmaceuticals: Azetukalner Has Shifted From Binary Science To Commercial Execution - Seeking Alpha
Xenon Pharmaceuticals: Azetukalner Has Shifted From Binary Science To Commercial Execution Seeking Alpha
Xenon Pharmaceuticals faces earnings test as launch nears By Investing.com - Investing.com Nigeria
Xenon Pharmaceuticals faces earnings test as launch nears By Investing.com Investing.com Nigeria
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo